The estimated Net Worth of Aubrey Rankin is at least 9.3 百万$ dollars as of 3 December 2021. Aubrey Rankin owns over 30,000 units of Revance Therapeutics Inc stock worth over 628,147$ and over the last 4 years he sold RVNC stock worth over 8,671,908$. In addition, he makes 0$ as Director at Revance Therapeutics Inc.
Aubrey has made over 11 trades of the Revance Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of RVNC stock worth 432,900$ on 3 December 2021.
The largest trade he's ever made was selling 55,382 units of Revance Therapeutics Inc stock on 26 July 2021 worth over 1,645,953$. On average, Aubrey trades about 24,842 units every 31 days since 2020. As of 3 December 2021 he still owns at least 95,463 units of Revance Therapeutics Inc stock.
You can see the complete history of Aubrey Rankin stock trades at the bottom of the page.
Aubrey Rankin is the Director at Revance Therapeutics Inc.
Aubrey's mailing address filed with the SEC is C/O REVANCE THERAPEUTICS, INC., 1222 DEMONBREUN STREET, SUITE 2000, NASHVILLE, TN, 37203.
Over the last 11 years, insiders at Revance Therapeutics Inc have traded over 29,070,398$ worth of Revance Therapeutics Inc stock and bought 136,530 units worth 2,014,047$ . The most active insiders traders include Vlad Coric、Julian S Gangolli、Angus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of 83,132$. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth 9,090$.
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
Revance Therapeutics Inc executives and other stock owners filed with the SEC include: